Clinical Trial Update: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH [Phase 1]

View source ↗

Summary

Phase 1 study of HMPL-306 in advanced hematologic cancers with IDH mutation has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• HMPL-306

Snippet

Sponsor: Hutchmed | Conditions: Isocitrate Dehydrogenase Gene Mutation | Phase 1 | Status: TERMINATED | Results posted: 2026-01-29